VIDEO: AVD-104 may offer next-generation treatment for geographic atrophy

Issue: November 25, 2023

ByBaruch D. Kuppermann, MD, PhD

ByMichela Cimberle

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective, Baruch D. Kuppermann, MD, PhD, speaks about AVD-104, a novel approach to the management of nonexudative macular degeneration, presented at the Euretina congress in Amsterdam.

AVD-104 (Aviceda Therapeutics) is a sialic acid-coated glycomimetic nanoparticle with a dual mechanism of action. In addition to inhibiting complement cascade amplification, it repolarizes proinflammatory macrophages to their resolution state. This novel treatment target for geographic atrophy also addresses the inflammatory component of neovascular AMD.

Kuppermann explains in detail the mechanism of action of AVD-104.

“We are excited about this new field of glycobiology, a potential new treatment approach for geographic atrophy that also has implications for neovascular AMD,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Kuppermann BD, et al. Modulation of macrophages and complement dysfunction in nonexudative AMD utilizing novel sialic-acid coated nanoparticles. Presented at: Euretina congress; Oct. 5-8, 2023; Amsterdam.

Disclosures: Kuppermann reports consulting for Allegro Ophthalmics, Allergan/AbbVie, Aviceda, Bausch + Lomb, Boehringer Ingelheim, Clearside, Coherus, EyeBio, Eyedaptic, EyePoint, Genentech, Glaukos, InflammX Therapeutics, Iveric Bio, jCyte, Neurotech Pharmaceuticals, Novartis Pharmaceuticals, Ocular Therapeutix, Outlook Therapeutics, Regeneron Pharmaceuticals, Re-Vana Therapeutics, Ripple Therapeutics, Stealth Biotherapeutics, TechImmune, Theravance Biopharma and Visgenx and performing clinical research for Apellis, Boehringer Ingelheim, EyePoint, Genentech, Ionis, Iveric Bio, Novartis Pharmaceuticals, Regeneron Pharmaceuticals and Regenxbio.

Euretina Congress

Read more

VIDEO: AVD-104 may offer next-generation treatment for geographic atrophy

Related Content